Main public logs

Combined display of all available logs of CAMIH. You can narrow down the view by selecting a log type, the username (case-sensitive), or the affected page (also case-sensitive).

• 14:44, 20 June 2024 CHoppe talk contribs created page Lin et al. (2010): Discrepancy of the effects of zinc supplementation on the prevention of radiotherapy-induced mucositis between patients with nasopharyngeal carcinoma and those with oral cancers: subgroup analysis of a double-blind, randomized study (Created page with "{{Reference |Reference=Publication: Discrepancy of the effects of zinc supplementation on the prevention of radiotherapy-induced mucositis between patients with nasopharyngeal carcinoma and those with oral cancers: subgroup analysis of a double-blind, randomized study }} =Brief summary= The analyses conducted in this publication included 83 patients with nasopharyngeal carcinoma (NPC) or oral carcinoma (OC), which were removed from a sample of Lin from 2006 with original...")
• 14:42, 20 June 2024 CHoppe talk contribs created page Publication: Discrepancy of the effects of zinc supplementation on the prevention of radiotherapy-induced mucositis between patients with nasopharyngeal carcinoma and those with oral cancers: subgroup analysis of a double-blind, randomized study (Created page with "{{Publication |Title=Discrepancy of the effects of zinc supplementation on the prevention of radiotherapy-induced mucositis between patients with nasopharyngeal carcinoma and those with oral cancers: subgroup analysis of a double-blind, randomized study |Topic=Zinc |Author=Lin, Y-S; Lin, L-C; Lin, S-W; Chang, C-P |Year=2010 |Journal=Nutrition and cancer |DOI=https://dx.doi.org/10.1080/01635581003605532 |Authors Abstract=The purpose of this study was to determine the effe...")
• 14:33, 20 June 2024 CHoppe talk contribs created page Lin et al. (2009): Effects of zinc supplementation on the survival of patients who received concomitant chemotherapy and radiotherapy for advanced nasopharyngeal carcinoma: follow-up of a double-blind randomized study with subgroup analysis (Created page with "{{Reference |Reference=Publication: Effects of zinc supplementation on the survival of patients who received concomitant chemotherapy and radiotherapy for advanced nasopharyngeal carcinoma: follow-up of a double-blind randomized study with subgroup analysis }} =Brief summary= =Study Design= {{Study Design (RCT) |Perspective=? |Centralized=? |Blinding=? |Is randomized=Yes |Cross-over=No |Number of arms=-999 }} =Study characteristics= {{RCT study general properties |Inc...")
• 14:32, 20 June 2024 CHoppe talk contribs deleted page Lin et al. (2010): Discrepancy of the effects of zinc supplementation on the prevention of radiotherapy-induced mucositis between patients with nasopharyngeal carcinoma and those with oral cancers: subgroup analysis of a double-blind, randomized study (wrong title and publication)
• 14:30, 20 June 2024 CHoppe talk contribs created page Publication: Effects of zinc supplementation on the survival of patients who received concomitant chemotherapy and radiotherapy for advanced nasopharyngeal carcinoma: follow-up of a double-blind randomized study with subgroup analysis (Created page with "{{Publication |Title={{Publication |Title=Effects of zinc supplementation on the survival of patients who received concomitant chemotherapy and radiotherapy for advanced nasopharyngeal carcinoma: follow-up of a double-blind randomized study with subgroup analysis |Topic=Zinc |Author=Lin, Y-S; Lin, L-C; Lin, S-W |Year=2009 |Journal=The Laryngoscope |DOI=10.1002/lary.20524 |Authors Abstract=Dietary zinc has been reported to have positive effects on treating carcinoma. This...")
• 14:29, 20 June 2024 CHoppe talk contribs deleted page Publication: Discrepancy of the effects of zinc supplementation on the prevention of radiotherapy-induced mucositis between patients with nasopharyngeal carcinoma and those with oral cancers: subgroup analysis of a double-blind, randomized study (wrong title)
• 14:17, 20 June 2024 CHoppe talk contribs created page Lin et al. (2010): Discrepancy of the effects of zinc supplementation on the prevention of radiotherapy-induced mucositis between patients with nasopharyngeal carcinoma and those with oral cancers: subgroup analysis of a double-blind, randomized study (Created page with "{{Reference |Reference=Publication: Discrepancy of the effects of zinc supplementation on the prevention of radiotherapy-induced mucositis between patients with nasopharyngeal carcinoma and those with oral cancers: subgroup analysis of a double-blind, randomized study }} =Brief summary= =Study Design= {{Study Design (RCT) |Perspective=? |Centralized=? |Blinding=? |Is randomized=Yes |Cross-over=No |Number of arms=-999 }} =Study characteristics= {{RCT study general prop...")
• 14:16, 20 June 2024 CHoppe talk contribs created page Publication: Discrepancy of the effects of zinc supplementation on the prevention of radiotherapy-induced mucositis between patients with nasopharyngeal carcinoma and those with oral cancers: subgroup analysis of a double-blind, randomized study (Created page with "{{Publication |Title=Discrepancy of the effects of zinc supplementation on the prevention of radiotherapy-induced mucositis between patients with nasopharyngeal carcinoma and those with oral cancers: subgroup analysis of a double-blind, randomized study |Topic=Zinc |Author=Lin, Y-S; Lin, L-C; Lin, S-W; Chang, C-P |Year=2010 |Journal=Nutrition and cancer |DOI=http://dx.doi.org/10.1080/01635581003605532 |Authors Abstract=The purpose of this study was to determine the effec...")
• 13:23, 20 June 2024 MKraft talk contribs created page Ota et al. (2014): The effect of pyridoxine for prevention of hand-foot-syndrome in colorectal cancer patients with adjuvant chemotherapy using capecitabine: A randomized study (Created page with "{{Reference |Reference=Publication: The effect of pyridoxine for prevention of hand-foot-syndrome in colorectal cancer patients with adjuvant chemotherapy using capecitabine: A randomized study }} =Brief summary= This study investigated the effect of vitamin B6 on chemotherapy side effects in patients with colorectal cancer. Half of the patients received a vitamin B6 preparation in addition to chemotherapy and the other half only chemotherapy. The two groups did not diff...")
• 13:22, 20 June 2024 MKraft talk contribs created page Publication: The effect of pyridoxine for prevention of hand-foot-syndrome in colorectal cancer patients with adjuvant chemotherapy using capecitabine: A randomized study (Created page with "{{Publication |Title=The effect of pyridoxine for prevention of hand-foot-syndrome in colorectal cancer patients with adjuvant chemotherapy using capecitabine: A randomized study |Topic=Vitamin B6 |Author=Sure, here is the list rewritten in the specified style: Ota, M.; Tatsumi, K.; Suwa, H.; Watanabe, J.; Watanabe, K.; Osada, S.; Tanaka, K.; Shoichi, F.; Ichikawa, Y.; Kunisaki, C.; Endo, I. |Year=2014 |Journal=Hepato-Gastroenterology |DOI=http://www.ncbi.nlm.nih.gov/pu...")
• 13:15, 20 June 2024 DDeel talk contribs created page Mayne et al. (2001): Randomized Trial of Supplemental beta-Carotene to Prevent Second Head and Neck Cancer (Created page with "{{Reference |Reference=Publication: Randomized Trial of Supplemental beta-Carotene to Prevent Second Head and Neck Cancer }} =Brief summary= =Study Design= {{Study Design (RCT) |Perspective=? |Centralized=? |Blinding=? |Is randomized=Yes |Cross-over=No |Number of arms=-999 }} =Study characteristics= {{RCT study general properties |Inclusion criteria=? |Exclusion criteria=? |N randomized=-999 |Analysis=? |Specifications on analyses=? |Countries of data collection=? |Lo...")
• 13:14, 20 June 2024 DDeel talk contribs created page Publication: Randomized Trial of Supplemental beta-Carotene to Prevent Second Head and Neck Cancer (Created page with "{{Publication |Title=Randomized Trial of Supplemental beta-Carotene to Prevent Second Head and Neck Cancer |Topic=Vitamin A (beta-carotene) |Author=Mayne, S; Cartmel, B; Baum, M; Shor-Posner, G; Fallon, B; Briskin, K; Bean, J; Zheng, T; Cooper, D; Friedman, C; Goodwin, W |Year=2001 |Journal=Cancer Research |DOI=https://pubmed.ncbi.nlm.nih.gov/11245451/ |Authors Abstract=β-carotene has established efficacy in animal models of oral carcinogenesis and has been shown to reg...")
• 13:03, 20 June 2024 EProba talk contribs created page Henning et al. (2015): Randomized Clinical Trial of Brewed Green and Black Tea in Men With Prostate Cancer Prior to Prostatectomy (Created page with "{{Reference |Reference=? }} =Brief summary= In this study, 113 patients with prostate cancer were randomly assigned to one of three groups. One group drank 6 cups of green tea (incl. 562mg EGCG) daily, the second 6 cups of black tea (incl. 28mg EGCG) and the third 6 cups of water as a control group. The participants and study leaders knew whether they had drunk tea or water, as it was not possible to prevent this due to the flavour. The patients drank the tea until the p...")
• 13:00, 20 June 2024 EProba talk contribs created page Henning, S. M.; Wang, P.; Said, J. W.; Huang, M.; Grogan, T.; Elashoff, D.; Carpenter, C. L.; Heber, D.; Aronson, W. J. (Created page with "{{Author}}")
• 12:57, 20 June 2024 EProba talk contribs created page Publication: Randomized Clinical Trial of Brewed Green and Black Tea in Men With Prostate Cancer Prior to Prostatectomy (Created page with "{{Publication |Title=Randomized Clinical Trial of Brewed Green and Black Tea in Men With Prostate Cancer Prior to Prostatectomy |Topic=Green tea (EGCG) |Author=Henning, S. M.; Wang, P.; Said, J. W.; Huang, M.; Grogan, T.; Elashoff, D.; Carpenter, C. L.; Heber, D.; Aronson, W. J. |Year=2015 |Journal=The Prostate |DOI=https://doi.org/10.1002/pros.22943 |Authors Abstract=Background. Preclinical and epidemiologic studies suggest chemopreventive effects of green tea (GT) and...")
• 12:48, 20 June 2024 CHoppe talk contribs created page Lin et al. (2008): Publication: Effects of zinc supplementation on clinical outcomes in patients receiving radiotherapy for head and neck cancers: a double-blinded randomized study (Created page with "{{Reference |Reference=Publication: Effects of zinc supplementation on clinical outcomes in patients receiving radiotherapy for head and neck cancers: a double-blinded randomized study }} =Brief summary= =Study Design= {{Study Design (RCT) |Perspective=? |Centralized=? |Blinding=? |Is randomized=Yes |Cross-over=No |Number of arms=-999 }} =Study characteristics= {{RCT study general properties |Inclusion criteria=? |Exclusion criteria=? |N randomized=-999 |Analysis=? |S...")
• 12:41, 20 June 2024 CHoppe talk contribs created page Publication: Effects of zinc supplementation on clinical outcomes in patients receiving radiotherapy for head and neck cancers: a double-blinded randomized study (Created page with "{{Publication |Title=Effects of zinc supplementation on clinical outcomes in patients receiving radiotherapy for head and neck cancers: a double-blinded randomized study |Topic=Zinc |Author=Lin, L-C; Que, J; Lin, K-L; Leung, HW-C; Lu, C-L; Chang, C-H |Year=2008 |Journal=nternational journal of radiation oncology, biology, physics |DOI=10.1016/j.ijrobp.2007.06.073 |Authors Abstract=Purpose: To evaluate the impact of zinc supplementation on the survival of patients after r...")
• 12:19, 20 June 2024 DDeel talk contribs moved page Jyothirmayi et al. (1996), Efficacy of Vitamin A in the Prevention of Locoregional Recurrence and Second Primaries in Head and Neck Cancer to Jyothirmayi et al. (1996): Efficacy of Vitamin A in the Prevention of Locoregional Recurrence and Second Primaries in Head and Neck Cancer without leaving a redirect
• 12:19, 20 June 2024 DDeel talk contribs moved page Ehrenpreis et al. (2005), A Prospective, Randomized, Double-Blind, Placebo-Controlled Trial of Retinol Palmitate (Vitamin A) for Symptomatic Chronic Radiation Proctopathy to Ehrenpreis et al. (2005): A Prospective, Randomized, Double-Blind, Placebo-Controlled Trial of Retinol Palmitate (Vitamin A) for Symptomatic Chronic Radiation Proctopathy without leaving a redirect
• 12:08, 20 June 2024 DDeel talk contribs moved page Ameliorative effect of lycopene effect on cisplatin-induced nephropathy in patients to Mahmoodnia et al. (2017): Ameliorative effect of lycopene effect on cisplatin-induced nephropathy in patients without leaving a redirect
• 12:07, 20 June 2024 DDeel talk contribs deleted page Mahmoodnia et al. (2017): Ameliorative effect of lycopene effect on cisplatin-induced nephropathy in patients (content was: "{{Reference |Reference=Publication: Ameliorative effect of lycopene effect on cisplatin-induced nephropathy in patients }} =Brief summary= In this study, a large sample of 120 cancer patients who had received cisplatin chemotherapy was examined. Half of the patients received lycopene in addition to chemotherapy and standard treatment to prevent kidney damage. Neither the particip...", and the only contributor was "MKraft" (talk))
• 09:06, 20 June 2024 CMensger talk contribs moved page Howells et al. (2011), Phase I randomised double-blind pilot study of micronized resveratrol (SRT501) in patients with hepatic metastases - safety, pharmacokinetics and pharmacodynamics to Howells et al. (2011): Phase I randomised double-blind pilot study of micronized resveratrol (SRT501) in patients with hepatic metastases - safety, pharmacokinetics and pharmacodynamics without leaving a redirect (comma to colon)
• 07:51, 20 June 2024 CMensger talk contribs created page Howells et al. (2011), Phase I randomised double-blind pilot study of micronized resveratrol (SRT501) in patients with hepatic metastases - safety, pharmacokinetics and pharmacodynamics (Created page with "{{Reference |Reference=Phase I randomised double-blind pilot study of micronized resveratrol (SRT501) in patients with hepatic metastases - safety, pharmacokinetics and pharmacodynamics }} =Brief summary= This study compared two groups of patients, all of whom had colorectal carcinoma (stage IV) with liver metastases and a life expectancy of less than 3 months. The patients received a resveratrol solution (5.0 g) or a matching placebo once a day for 14 days prior to surg...")
• 07:35, 20 June 2024 CMensger talk contribs created page Gescher, AJ (Created page with "{{Author}}")
• 07:35, 20 June 2024 CMensger talk contribs created page Steward, WP (Created page with "{{Author}}")
• 07:34, 20 June 2024 CMensger talk contribs created page Brown, K (Created page with "{{Author}}")
• 07:34, 20 June 2024 CMensger talk contribs created page Hegarty, B (Created page with "{{Author}}")
• 07:34, 20 June 2024 CMensger talk contribs created page Hoffmann, E (Created page with "{{Author}}")
• 07:33, 20 June 2024 CMensger talk contribs created page Jacobson, EW (Created page with "{{Author}}")
• 07:33, 20 June 2024 CMensger talk contribs created page Elliott, PJ (Created page with "{{Author}}")
• 07:33, 20 June 2024 CMensger talk contribs created page Berry, DP (Created page with "{{Author}}")
• 07:32, 20 June 2024 CMensger talk contribs created page Howells, LM (Created page with "{{Author}}")
• 10:04, 19 June 2024 MKraft talk contribs created page Yap et al. (2017): Predictors of hand-foot syndrome and pyridoxine for prevention of capecitabine-induced hand-foot syndrome: a randomized clinical trial (Created page with "{{Reference |Reference=Publication: Predictors of hand-foot syndrome and pyridoxine for prevention of capecitabine-induced hand-foot syndrome: a randomized clinical trial }} =Brief summary= This study also investigated the effect of vitamin B6 on chemotherapy side effects in patients with different types of cancer. At the start of chemotherapy, half of the patients were given a vitamin B6 preparation and the other half a placebo. The two groups did not differ in terms of...")
• 09:53, 19 June 2024 EProba talk contribs created page Emami et al. (2014): Double-blinded, randomized, placebo-controlled study to evaluate the effectiveness of green tea in preventing acute gastrointestinal complications due to radiotherapy (Created page with "{{Reference |Reference=? }} =Brief summary= In this study, 42 patients receiving standardised abdominal or pelvic radiotherapy were randomly assigned to one of two groups. One group received a 450mg green tea tablet and the other group received a placebo tablet, each once daily for 5 weeks. Neither the participants nor the study leaders knew whether they were receiving the tablet with green tea or without the active ingredient. The frequency and severity of diarrhoea and...")
• 09:42, 19 June 2024 EProba talk contribs created page Emami, H., Nikoobin, F., Roayaei, M., Ziya, H. R. (Created page with "{{Author}}")
• 09:40, 19 June 2024 MKraft talk contribs created page Publication: Predictors of hand-foot syndrome and pyridoxine for prevention of capecitabine-induced hand-foot syndrome: a randomized clinical trial (Created page with "{{Publication |Title=Predictors of hand-foot syndrome and pyridoxine for prevention of capecitabine-induced hand-foot syndrome: a randomized clinical trial |Topic=Vitamin B6 |Author=Yap, Y.; Kwok, L.; Syn, N.; Chay, W. Y.; Chia, J. W. K.; Tham, C. K.; Wong, N. S.; Lo, S. K.; Dent, R. A.; Tan, S.; Mok, Z. Y.; Koh, K. X.; Toh, H. C.; Koo, W. H.; Loh, M.; Ng, R. C. H.; Choo, S. P.; Soong, R. C. T. |Year=2017 |Journal=JAMA Oncology |DOI=https://doi.org/10.1001/jamaoncol.2017...")
• 09:38, 19 June 2024 EProba talk contribs created page Publication: Double-blinded, randomized, placebo-controlled study to evaluate the effectiveness of green tea in preventing acute gastrointestinal complications due to radiotherapy (Created page with "{{Publication |Title=Publication: Double-blinded, randomized, placebo-controlled study to evaluate the effectiveness of green tea in preventing acute gastrointestinal complications due to radiotherapy |Topic=Green tea (EGCG) |Author=Emami, H.; Nikoobin, F.; Roayaei, M.; Ziya, H. R. |Year=2014 |Journal=Journal of Research in Medical Sciences: The official journal of Isfahan University of Medical Sciences |DOI=PMCID: PMC4116577 |Authors Abstract=Background: Radiation-induc...")
• 07:46, 19 June 2024 MKraft talk contribs created page Newling et al. (1995): Tryptophan metabolites, pyridoxine (vitamin B6) and their influence on the recurrence rate of superficial bladder cancer. Results of a prospective, randomised phase III study performed by the EORTC GU Group (Created page with "{{Reference |Reference=Publication: Tryptophan metabolites, pyridoxine (vitamin B6) and their influence on the recurrence rate of superficial bladder cancer. Results of a prospective, randomised phase III study performed by the EORTC GU Group }} =Brief summary= This study primarily investigated the effect of vitamin B6 in bladder cancer patients on disease-free survival and the recurrence rate. In addition, tumor progression and overall survival were considered. Ther...")
• 07:44, 19 June 2024 MKraft talk contribs created page Publication: Tryptophan metabolites, pyridoxine (vitamin B6) and their influence on the recurrence rate of superficial bladder cancer. Results of a prospective, randomised phase III study performed by the EORTC GU Group (Created page with "{{Publication |Title=Tryptophan metabolites, pyridoxine (vitamin B6) and their influence on the recurrence rate of superficial bladder cancer. Results of a prospective, randomised phase III study performed by the EORTC GU Group |Topic=Vitamin B6 |Author=Newling, D; Robinson, M; Smith, P; Byar, D; Lockwood, R; Stevens, I; De Pauw, M; Sylvester, R |Year=1995 |Journal=European urology. |DOI=https://doi.org/10.1159/000475139 |Authors Abstract=This double-blind randomised pha...")
• 14:49, 18 June 2024 MKraft talk contribs created page Braik et al. (2014): Randomized trial of vitamin B6 for preventing hand-foot syndrome from capecitabine chemotherapy (Created page with "{{Reference |Reference=Publication: Randomized trial of vitamin B6 for preventing hand-foot syndrome from capecitabine chemotherapy }} =Brief summary= This study investigated the effect of vitamin B6 on chemotherapy side effects in patients with different types of cancer. At the start of chemotherapy, half of the patients were given a vitamin B6 preparation and the other half a placebo. The two groups did not differ in terms of the number of people with hand-foot syndrom...")
• 14:33, 18 June 2024 MKraft talk contribs created page Publication: Randomized trial of vitamin B6 for preventing hand-foot syndrome from capecitabine chemotherapy (Created page with "{{Publication |Title=Randomized trial of vitamin B6 for preventing hand-foot syndrome from capecitabine chemotherapy |Topic=Vitamin B6 |Author=Braik, T; Yim, B; Evans, A T; Kassem, M; Mullane, M; Lad, T; Hussein, L; Cleveland, B; McDunn, S |Year=2014 |Journal=PloS one |DOI=https://doi.org/10.12788/jcso.0017 |Authors Abstract=Background: Capecitabine is an oral fuoropyrimidine that is used to treat various malignancies. Hand-foot syndrome (HFS) is a dose-limiting toxicity...")
• 09:19, 18 June 2024 DDeel talk contribs created page Margalit et al. (2012): Beta-carotene Antioxidant Use During Radiation Therapy and Prostate Cancer Outcome in the Physicians’ Health Study (Created page with "{{Reference |Reference=Publication: Beta-carotene Antioxidant Use During Radiation Therapy and Prostate Cancer Outcome in the Physicians’ Health Study }} =Brief summary= This study investigated whether the administration of beta-carotene (i.e. a precursor of vitamin A) in addition to radiotherapy shortens the survival time or causes metastases to appear earlier. There were no differences between patients who received radiotherapy and beta-carotene and those who receive...")
• 09:10, 18 June 2024 DDeel talk contribs created page Publication: Beta-carotene Antioxidant Use During Radiation Therapy and Prostate Cancer Outcome in the Physicians’ Health Study (Created page with "{{Publication |Title=Beta-carotene Antioxidant Use During Radiation Therapy and Prostate Cancer Outcome in the Physicians’ Health Study |Topic=Vitamin A (beta-carotene) |Author=Margalit, DN; Kasperzyk, JL; Martin, NE; Sesso, HD; Gaziano, JM; Ma, J; Stampfer, MJ; Mucci, LA |Year=2012 |Journal=International journal of radiation oncology, biology, physics |DOI=https://doi.org/10.1016/j.ijrobp.2011.05.032 |Authors Abstract=Purpose: The safety of antioxidant supplementation...")
• 11:57, 17 June 2024 JDoerfler talk contribs created page Publication: Selenium Substitution During Radiotherapy of Solid Tumours Laboratory Data from Two Observation Studies in Gynaecological and Head and Neck Cancer Patients (Created page with "{{Publication |Title=Selenium Substitution During Radiotherapy of Solid Tumours Laboratory Data from Two Observation Studies in Gynaecological and Head and Neck Cancer Patients |Topic=Selenium |Author=Büntzel, J; Micke, O; Kisters, K; Bruns, F; Glatzel, M; Schänekaes, K; Kundt, C; Schäfer, U; Mücke, R |Year=2010 |Journal=Anticancer Research |DOI=https://ar.iiarjournals.org/content/30/5/1783.short |Authors Abstract=Objective: Selenium is an essential cofactor of the e...")
• 12:43, 14 June 2024 JDoerfler talk contribs created page Muecke et al. (2014): Multicenter, phase 3 trial comparing selenium supplementation with observation in gynecologic radiation oncology: follow-up analysis of the survival data 6 years after cessation of randomization (Created page with "{{Reference |Reference=Publication: Multicenter, phase 3 trial comparing selenium supplementation with observation in gynecologic radiation oncology: follow-up analysis of the survival data 6 years after cessation of randomization }} =Brief summary= =Study Design= {{Study Design (RCT) |Perspective=? |Centralized=? |Blinding=? |Is randomized=Yes |Cross-over=No |Number of arms=-999 }} =Study characteristics= {{RCT study general properties |Inclusion criteria=? |Exclusio...")
• 12:42, 14 June 2024 JDoerfler talk contribs created page Publication: Multicenter, phase 3 trial comparing selenium supplementation with observation in gynecologic radiation oncology: follow-up analysis of the survival data 6 years after cessation of randomization (Created page with "{{Publication |Title=Multicenter, phase 3 trial comparing selenium supplementation with observation in gynecologic radiation oncology: follow-up analysis of the survival data 6 years after cessation of randomization |Topic=Selenium |Author=Muecke, R; Micke, O; Schomburg, L; Glatzel, M; Reichl, B; Kisters, K; Schaefer, U; Huebner, J; Eich, HT; Fakhrian, K; Adamietz, IA; Buentzel, J |Year=2014 |Journal=Integrative Cancer Therapies |DOI=10.1177/1534735414541963 |Authors Abs...")
• 12:14, 14 June 2024 JDoerfler talk contribs created page Muecke et al. (2013): Impact of treatment planning target volumen (PTV) size on radiation induced diarrhoea following selenium supplementation in gynecologic radiation oncology--a subgroup analysis of a multicenter, phase III trial (Created page with "{{Reference |Reference=Publication: Impact of treatment planning target volumen (PTV) size on radiation induced diarrhoea following selenium supplementation in gynecologic radiation oncology--a subgroup analysis of a multicenter, phase III trial }} =Brief summary= =Study Design= {{Study Design (RCT) |Perspective=? |Centralized=? |Blinding=? |Is randomized=Yes |Cross-over=No |Number of arms=-999 }} =Study characteristics= {{RCT study general properties |Inclusion crite...")
• 12:11, 14 June 2024 JDoerfler talk contribs created page Publication: Impact of treatment planning target volumen (PTV) size on radiation induced diarrhoea following selenium supplementation in gynecologic radiation oncology--a subgroup analysis of a multicenter, phase III trial (Created page with "{{Publication |Title=Impact of treatment planning target volumen (PTV) size on radiation induced diarrhoea following selenium supplementation in gynecologic radiation oncology--a subgroup analysis of a multicenter, phase III trial |Topic=Selenium |Author=Muecke, R; Micke, O; Schomburg, L; Buentzel, J; Glatzel, M; Baaske, D; Berndt-Skorka, R; Prott, FJ; Reichl, B; Kisters, K; Schaefer, U; Huebner, J; Eich, HT; Kundt, G; Adamietz, IA |Year=2013 |Journal=Radiation Oncology...")
• 09:06, 14 June 2024 MKraft talk contribs created page Puri et al. (2010): Lycopene in treatment of high-grade gliomas: A pilot study (Created page with "{{Reference |Reference=Publication: Lycopene in treatment of high-grade gliomas: A pilot study }} =Brief summary= =Study Design= {{Study Design (RCT) |Perspective=? |Centralized=? |Blinding=? |Is randomized=Yes |Cross-over=No |Number of arms=-999 }} =Study characteristics= {{RCT study general properties |Inclusion criteria=? |Exclusion criteria=? |N randomized=-999 |Analysis=? |Specifications on analyses=? |Countries of data collection=? |LoE=? |Outcome timeline=? }}...")
• 09:03, 14 June 2024 MKraft talk contribs created page Publication: Lycopene in treatment of high-grade gliomas: A pilot study (Created page with "{{Publication |Title=Lycopene in treatment of high-grade gliomas: A pilot study |Topic=Lycopene |Author=Puri, T.; Goyal, S.; Julka, P. K.; Nair, O.; Sharma, D. N.; Rath, G. K. |Year=2010 |Journal=Neurology India |DOI=https://doi.org/10.4103/0028-3886.60389 |Authors Abstract=Background: The therapeutic benefit of lycopene is well established for carcinoma prostate in various clinical trials and has been proposed for other malignancies including high-grade gliomas. Se...")